Program

Program Wednesday, 8 November 2017

7:30 - 8:30
EDUCATIONAL SYMPOSIUM
7:30 - 8:30
Room: Lomond Auditorium (Loch Suite)
UNIVERSAL VALUE: THE WAY FORWARD?

(Sponsored by Covance)

8:00 - 15:30
SPEAKER READY ROOM HOURS (Fyne-Loch Suite)
Room: Fyne (Loch Suite)
8:00 - 16:00
REGISTRATION HELP DESK HOURS (Hall 5)
Room: Hall 5
8:30 - 14:15
EXHIBIT/POSTER HALL HOURS (Hall 4)
Room: Hall 4
8:45 - 9:45
BREAKOUT SESSION

8:45 - 9:45
Room: Hall 3

IP17: DERIVING UTILITY MEASURES FROM DISEASE-SPECIFIC QUALITY OF LIFE INSTRUMENTS: DOES MAPPING TO GENERIC UTILITY INSTRUMENTS ADEQUATELY CAPTURE THE PATIENT PERSPECTIVE IN ECONOMIC EVALUATION?

Moderator:

Samuel Aballéa, PhD, Vice President, HEOR, Creativ-Ceutical, Paris, France

Panelists:

Linda Abetz-Webb, MA, Senior Research Director, Patient-Centred Outcomes Assessments, Bollington, UK

Keith Tolley, Director, Tolley Health Economics Ltd., Buxton, UK

Clément François, PhD, Vice President, Health Economics and Outcomes Research, Lundbeck, Deerfield, IL, USA


8:45 - 9:45
Room: Hall 2

IP18: HOW WILL HEALTH CARE SYSTEMS HANDLE FUTURE ONCOLOGY COMBINATION PRODUCT LAUNCHES?

Moderator:

Bettina Ryll, MD, PhD, Founder, and Researcher, Melanoma Patient Network Europe, and Uppsala University (Department EBC), Uppsala, Sweden

Panelists:

Martina Weiss-Radtke, MBA, Head Negotiation/Reimbursement Pharmaceuticals, Helsana Versicherungen AG, Zurich, Switzerland

Jens Grueger, PhD, Vice President & Head of Global Pricing & Market Access, F. Hoffmann-LaRoche, Division Pharma, Basel, Switzerland

Meindert Boysen, PharmD, MSc, Programme Director Technology Appraisals, National Institute for Health and Care Excellence, Manchester, UK


8:45 - 9:45
Room: Lomond Auditorium (Loch Suite)

IP19: CAN THE PATIENT VOICE BE BETTER INCORPORATED INTO THE NICE PROCESS?

Moderator:

Eric Low, NA, Former CEO of Myeloma UK, N/A, East Lothian, UK

Panelists:

Jennifer Lee, MBA, HEMAR & Advocacy Director, Health Economics, Market Access, Reimbursement, & Advocacy, Janssen UK, High Wycombe, UK

Heidi Livingstone, BA, Project Manager, Patient and Public Involvement Manager, NICE, London, UK

Richard Jackson, PGCE, NPQH, Patient Expert (Currently a Primary School Headteacher), NA (Hillview Primary School), NA, UK


8:45 - 9:45
Room: Hall 1
W17: COMPARING, CONTRASTING, AND VALIDATING HEALTH ECONOMIC DECISION MODELS: EXPERIENCES FROM THE LATEST MT. HOOD CHALLENGE IN DIABETES AND LESSONS FOR OTHER DISEASE AREAS
Discussion Leaders:

Alan Brennan, PhD, Professor of Health Economics and Decision Modelling, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Mark Lamotte, MD, Cardiologist, Senior principal, RWES, QuintilesIMS, Zaventem, Belgium

Talitha Feenstra, PhD, Senior Researcher / Assistant Professor, RIVM /UMCG, Bilthoven, The Netherlands

Michael Willis, PhD, Research Director, The Swedish Institute for Health Economics, Lund, Sweden


8:45 - 9:45
Room: Forth (Armadillo)
W18: FROM ONE TO MANY: WHEN GROUPS – NOT CZARS – MAKE DECISIONS
Discussion Leaders:

Charles E. Phelps, PhD, MBA, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA

Guruprasad Madhavan, PhD, Senior Program Officer, Health and Medicine, National Academies of Science, Engineering, and Medicine, Washington, DC, USA

8:45 - 14:00
RESEARCH POSTER PRESENTATIONS - SESSION V
9:45 - 10:00
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V (Hall 4)
Room: Hall 4
10:00 - 11:00
BREAKOUT SESSION

10:00 - 11:00
Room: Hall 3

IP20: SHOULD ICER BE NICE (OR NOT)? HOW ICER’S NEW COST-EFFECTIVENESS FRAMEWORK COMPARES WITH NICE’S GUIDELINES

Moderator:

Matthew Sussman, MA, Associate Managing Director/Director, Modeling & Evidence, Boston Health Economics, Waltham, MA, USA

Panelists:

Dan Ollendorf, PhD, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, MA, USA

Pall Jonsson, PhD, Associate Director, Research and Development, National Institute for Health and Care Excellence (NICE), Manchester, UK


10:00 - 11:00
Room: Hall 2

IP21: ADAPTIVE PATHWAYS FOR TRANSFORMATIVE MEDICINAL PRODUCTS: A NEW PARADIGM WITH THE ENHANCED APPLICATION OF REAL-WORLD EVIDENCE?

Moderator:

David Schwicker, MA, Principal, ORPHA Strategy Consulting, Basle, Switzerland

Panelists:

Nicola Bedlington, Secretary General, European Patients’ Forum and Co-Founder, The Patient Access Partnership PACT, Brussels, Belgium

Ad Schuurman, MA, Head of the International Department, National Health Care Institute (ZIN), AH, The Netherlands

Rob Thwaites, MA, MCom, Senior Director, Takeda, London, UK


10:00 - 11:00
Room: Lomond Auditorium (Loch Suite)

IP22: HOW CAN WE ASSESS THE VALUE OF NEW ANTIBIOTICS?

Moderator:

Chris Henshall, PhD, Independent Consultant and Visiting Fellow, Office of Health Economics, London, UK, UK

Panelists:

Alec Morton, PhD, Professor of Management Science, Department of Management Science, Strathclyde Business School, University of Strathclyde, Glasgow, Scotland, UK

Douglas Lundin, PhD, Chief Economist, TLV, Stockholm, Sweden

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK


10:00 - 11:00
Room: Hall 1
W19: GENERATING EVIDENCE TO SUPPORT OFF-LABEL HIGHER VALUE CANCER TREATMENT REGIMENS
Discussion Leaders:

Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK

Mark J. Ratain, MD, FASCO, Leon O. Jacobson Professor, Department of Medicine, The University of Chicago, CHICAGO, IL, USA

Peter Clark, MA, MD, FRCP, Professor, The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK

Virginia Acha, PhD, Executive Director, EU, EMEA, APAC Regulatory Policy, MSD Ltd., Hertfordshire, UK


10:00 - 11:00
Room: Forth (Armadillo)
W20: DISCONNECTED OR LIMITED EVIDENCE IN NETWORK META-ANALYSIS: WHAT CAN BE DONE?
Discussion Leaders:

Howard Thom, BA, MSc, PhD, Research Fellow in Statistical Modelling, School of Social and Community Medicine, University of Bristol, Bristol, UK

Joy Leahy, BSc, PhD Student, School of Computer Science and Statistics, Trinity College Dublin, Dublin 2, Ireland

Jeroen P. Jansen, PhD, MSc, Chief Scientist of Evidence Synthesis and Decision Modeling, Evidence Synthesis and Decision Modeling, Precision Health Economics, Vancouver, BC, Canada

11:15 - 12:45
WELCOME & THIRD PLENARY SESSION
Room: Clyde Auditorium (Armadillo)
WELCOME FROM ISPOR PRESIDENT
Speaker: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Room: Clyde Auditorium (Armadillo)
ISPOR DISTINGUISHED SERVICE AWARDS
Presented by: Shelby D. Reed, PhD, RPh, Professor, Duke University, Durham, NC, USA
AWARDEE: Andrew Briggs, DPhil bio
William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK
AWARDEE: Maarten J. IJzerman, PhD bio
Professor & Vice-Dean, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
Room: Clyde Auditorium (Armadillo)
ISPOR 21ST ANNUAL EUROPEAN CONGRESS ANNOUNCEMENT
Speaker: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Room: Clyde Auditorium (Armadillo)
THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC
As the rate of medical innovation accelerates, competing demands from various stakeholders put unprecedented pressure on health systems to deliver high-value medical care. Most health systems claim to link coverage decisions to the value for money afforded by specific treatments, but their approaches to valuation differ. Many countries, such as the United Kingdom, have historically relied on traditional cost-effectiveness analysis using the cost-per-QALY metric to guide coverage decisions. Other countries like France and Germany never adopted the uncertain place of cost-utility analysis in the decision processes", relying instead on disease-specific metrics. The large majority of payers in the pluralistic US health care market deny explicit consideration of cost effectiveness in coverage decisions, and US law forbids its use as part of the Affordable Care Act. Instead, public and private payers in the United States increasingly push financial risk onto health care providers thereby, in a sense, decentralizing the assessment of value.  Health economists from the United Kingdom, the United States, and France will provide reflective views on how valuation of medical technologies has changed across time and will discuss the methodological, societal, and political forces that shaped their evolution. The speakers will also consider what the future holds for valuation in health.  
Moderator: Shelby D. Reed, PhD, RPh bio
Professor, Duke University, Durham, NC, USA
Speaker: Mandy Ryan, PhD, MSc bio
Director of the Health Economics Research Unit, Institute of Applied Health Sciences, College of Life Sciences and Medicine, University of Aberdeen, Aberdeen, UK
Speaker: Charles E. Phelps, PhD bio
University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA
Speaker: Jérôme Wittwer, PhD bio
Professor, Economics, Bordeaux University, Bordeaux, France
12:45 - 14:15
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V (Hall 4)
Room: Hall 4
13:00 - 14:00
EDUCATIONAL SYMPOSIUM
13:00 - 14:00
Room: Lomond Auditorium (Loch Suite)
DOES ACCELERATED APPROVAL DELIVER ACCELERATED ACCESS? EXPERIENCES, CHALLENGES AND PRIORITIES

(Sponsored by AstraZeneca)

13:00 - 14:00
POSTER AUTHOR DISCUSSION HOUR - SESSION V (Hall 4)
Room: Hall 4
14:15 - 15:15
BREAKOUT SESSION

14:15 - 15:15
Room: Hall 3

IP23: HOW DO YOU INCORPORATE THE PATIENT PERSPECTIVE INTO HEALTH TECHNOLOGY ASSESSMENTS? DEFINING BEST PRACTICES FOR RIGOROUS SCIENTIFIC EVIDENCE AND IMPACTFUL SUBMISSIONS AND REVIEWS

Moderator:

Judith Leah Rubinstein, MIA, Director of Regulatory Data, Context Matters Inc., New York, NY, USA

Panelists:

Paola Kruger, MA, Patient Expert-EUPATI Fellow, Accademia dei Pazienti/EUPATI Italia, Rome, Italy

Ken Bond, MA, Director, Patient Engagement, Ethics, and International Affairs, CADTH, Ottawa, ON, Canada

Laure Delbecque, PhD, Associate Director, Pharmerit International, Rotterdam, The Netherlands


14:15 - 15:15
Room: Hall 2

IP24: TRUSTING THE RESULTS OF MODEL-BASED ECONOMIC ANALYSES: IS THERE A PRAGMATIC VALIDATION SOLUTION?

Moderator:

J. Jaime Caro, MDCM, Adjunct Professor of Medicine, Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada

Panelists:

Matt Stevenson, PhD, Professor of Health Technology Assessment, ScHARR, University of Sheffield, Sheffield, UK

Jorgen Moller, MSc, Mech Eng, Vice President of Modeling Technologies, Modelling Technologies and Simulation, Evidera, Hammersmith, UK

Salah Ghabri, PhD, Senior Health Economist, Haute Autorité de Santé, Saint-Denis La Plaine, France


14:15 - 15:15
Room: Forth (Armadillo)

IP25: INNOVATIVE CLINICAL TRIAL DESIGNS: WELCOMED BY REGULATORS BUT WHAT ABOUT THE PAYERS?

Moderator:

Richard Macaulay, PhD, Principal Consultant, PAREXEL Access Consulting, PAREXEL International, London, UK

Panelists:

Leanne Larson, MHA, Vice President & Global Head, Observational Research, PAREXEL International, Waltham, MA, USA

Andrew Walker, PhD, Director, Salus Alba Consulting, Glasgow, UK

Detlev Parow, MD, MBA, Head of Health Care Management Development, D A K - Gesundheit, Hamburg, Germany


14:15 - 15:15
Room: Hall 1
W21: COMPARING TREATMENTS BY COMBINING DATA FROM VARIOUS RANDOMIZED AND OBSERVATIONAL STUDIES: INTRODUCTION TO CONCEPT, METHODS, AND APPLICATION
Discussion Leaders:

Viktor Chirikov, PhD, Scientist, Pharmerit International, Bethesda, MD, USA

Susanne Schmitz, PhD, Postdoctoral Fellow, Department of Population Health / Health Economics and Evidence Synthesis Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg

Farhan Mughal, MRPharmS, MSc, Associate Director, Health Economics and Outcomes Research, Celgene Ltd, Uxbridge, UK


14:15 - 15:15
Room: Lomond Auditorium (Loch Suite)
W22: NEGOTIATING PRICE AND DATA IN AN ERA OF CONDITIONAL APPROVAL: “STICK” OR “TWIST”?
Discussion Leaders:

Daniel Gladwell, MSc, Principal Consultant, BresMed Health Solutions LTD, Sheffield, UK

Warren Cowell, MSc, National Market Access Policy Lead, Janssen Inc., High Wycombe, UK

Alan Brennan, PhD, Professor, University of Sheffield, Sheffield, UK

Ash Bullement, BSc, Health Economist, BresMed Health Solutions, Sheffield, UK

14:45 - 15:00
BREAK
15:30 - 16:30
BREAKOUT SESSION

15:30 - 16:30
Room: Forth (Armadillo)

IP26: MHEALTH AMONG CLINICIANS AND PATIENTS IN CANCER CARE: HOW TO ADDRESS THE DIGITAL DIVIDE?

Moderator:

Rosanna Tarricone, PhD, Associate Dean, Government & Health Division, SDA Bocconi, Director, Centre for Research on Health and Social Care Management, Associate Professor, Department of Policy Analysis and Public Management, Bocconi University, Milan, Italy

Panelists:

Maria Cucciniello, PhD, Assistant Professor, Centre for Research on Health and Social Care Management (CERGAS) and Department of Policy Analysis and Public Management, Bocconi University, Milan, Italy

Roma Maguire, PhD, MSc, Professor, School of Health Sciences Faculty of Health & Medical Sciences, University of Surrey, Glasgow, UK

Nicola Scalzo, MSc, Policy and Legal Officer, DG for Internal Market, Industry, Entrepreneurship and SMEs Health Technology and Cosmetics Unit GROW D.4, European Commission, Brussels, Belgium


15:30 - 16:30
Room: Hall 2

IP27: VALUING CHILDREN'S HRQoL FOR HEALTH TECHNOLOGY ASSESSMENT: WHAT ARE THE ISSUES AND CHALLENGES?

Moderator:

Nancy Devlin, PhD, Director of Research, Office of Health Economics, London, UK

Panelists:

Oliver Rivero-Arias, PhD, MSc, Senior Health Economist, National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK

Donna Rowen, PhD, Senior Research Fellow, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Deborah Morrison, MSc, BSc, Senior Scientific Adviser, NICE Scientific Advice, Centre for Health Technology Evaluation, NICE, Manchester, UK


15:30 - 16:30
Room: Hall 1

IP28: PATIENT PREFERENCES IN EUROPEAN DRUG REGULATION – ARE WE READY?

Moderator:

Douwe Postmus, PhD, Researcher, Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Panelists:

Francesco Pignatti, MD, Head of Oncology, Haematology, Diagnostics, European Medicines Agency, London, UK

Pierre Demolis, MD, PhD, Chairman Oncology Working Party of the CHMP, Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Saint-Denis, France

Tommi Tervonen, PhD, Research Scientist, Evidera, London, UK


15:30 - 16:30
Room: Lomond Auditorium (Loch Suite)
W23: IMPROVING PERFORMANCE OF ALGORITHMS TO POWER UNMET NEED AND EFFECTIVENESS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH USING ELECTRONIC HEALTH RECORDS AND HEALTH CARE CLAIMS DATA SOURCES
Discussion Leaders:

Hoa Van Le, MD, PhD, Senior Consultant, PAREXEL INTERNATIONAL, DURHAM, NC, USA

Aaron WC Kamauu, MD, MS, MPH, CEO, Anolinx LLC, Salt Lake City, UT, USA

Schiffon L Wong, MPH, Franchise Head Neurology, Global Evidence & Value Development, Global Research & Development, EMD Serono, Inc., Billerica, MA, USA

Monica Gaines Kobayashi, PhD, MBMA, Consultant, Real World Evidence & Data Analytics, PAREXEL International, Durham, NC, USA


15:30 - 16:30
Room: Hall 3
W24: POPULATION-ADJUSTED TREATMENT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT: AN OVERVIEW OF APPROACHES AND PERSPECTIVES
Discussion Leaders:

David M. Phillippo, MSc, BSc, Research Associate in Evidence Synthesis, School of Social and Community Medicine, University of Bristol, Bristol, UK

Ahmed Elsada, MSc, BSc, Technical Adviser, National Institute for Health and Clinical Excellence, Manchester, UK

Mark Belger, BSc, Principal Research Scientist, Eli Lilly and Company, Surrey, UK

Nicky J. Welton, PhD, MSc, Reader in Statistical and Health Economic Modelling, School of Social and Community Medicine, University of Bristol, Bristol, UK

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.